Correction: Ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis or chronic obstructive pulmonary disease, and in healthy volunteers (Journal of Aerosol Medicine and Pulmonary Drug Delivery (2017) 30:1 (53-63) DOI: 10.1089/jamp.2015.1282);Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 30, Issue 1, 2017, Pages 53-63

  Stass, Heino ^a   Nagelschmitz, Johannes ^a   Kappeler, Dominik ^b   Sommerer, Knut ^b   Kietzig, Claudius ^b   Weimann, Boris ^c  

^a BAYER PHARMA AG   (Germany)

^b Inamed GmbH   (Germany)

^c Chrestos Concept GmbH and Co KG   (Germany)

Author keywords

charcoal block; chronic obstructive pulmonary disease; Ciprofloxacin DPI (dry powder for inhalation); COPD; lung deposition; NCFB; non cystic fibrosis bronchiectasis; scintigraphy

Indexed keywords

CIPROFLOXACIN; TECHNETIUM 99M; ANTIINFECTIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG RELEASE; DRUG URINE LEVEL; DRY POWDER; DYSGEUSIA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL ABSORPTION; HEADACHE; HEMATOMA; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON CYSTIC FIBROSIS BRONCHIECTASIS; PERIORBITAL HEMATOMA; PHASE 1 CLINICAL TRIAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL; RASH; REPRODUCIBILITY; RHINOPHARYNGITIS; SCINTIGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOAVAILABILITY; CASE CONTROL STUDY; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRY POWDER INHALER; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TISSUE DISTRIBUTION; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; BRONCHIECTASIS; CASE-CONTROL STUDIES; CIPROFLOXACIN; CROSS-OVER STUDIES; DRY POWDER INHALERS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 85010280577     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2017.29009.hs.correx     Document Type: Erratum

References (36)

1. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, and Wilson R: Mortality in bronchiectasis: A long-term study assessing the factors influencing survival. Eur Respir J. 2009;34:843-849.
2. Seitz AE, Olivier KN, Adjemian J, Holland SM, and Prevots R: Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142:432-439.
3. O'Donnell AE: Bronchiectasis. Chest. 2008;134:815-823.
4. McDonnell MJ, Ward C, Lordan JL, and Rutherford RM: Non-cystic fibrosis bronchiectasis. Q J Med. 2013;106:709-715.
5. Smith MP: Non-cystic fibrosis bronchiectasis. J R Coll Physicians Edinb. 2011;41:132-139.
6. Angrill J, Agusti C, de Celis R, Raño A, Gonzalez J, Solé T, Xaubet A, Rodriguez-Roisin R, and Torres A: Bacterial colonisation in patients with bronchiectasis: Microbiological pattern and risk factors. Thorax. 2002;57:15-19.
7. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, and Hill AT: Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012; 186:657-665.
8. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, and Hill AT: The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014; 189:576-585.
9. Pasteur MC, Bilton D, and Hill AT; on behalf of the British Thoracic Society Bronchiectasis non-CF Guideline Group: British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1-i58.
10. Rademacher J, and Welte T: Bronchiectasis-diagnosis and treatment. Dtsch Arztebl Int. 2011;108:809.
11. Stass H, Weimann B, Nagelschmitz J, Rolink-Werninghaus C, and Staab D: Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: A phase I, randomized, dose-escalation study. Clin Ther. 2013;35:1571-1581.
12. Stass H, Delesen H, Nagelschmitz J, and Staab D: Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: A phase I, randomized, single-dose, doseescalation study. J Aerosol Med Pulm Drug Deliv. 2015; 28:106-115.
13. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, Alder J, Reimnitz P, and Hampel B: Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: A phase II randomised study. Eur Respir J. 2013;41:1107-1115.
14. Newman S, Bennett WD, Biddiscombe M, Devadason SG, Dolovich MB, Fleming J, Haeussermann S, Kietzig C, Kuehl PJ, Laube BL, Sommerer K, Taylor G, Usmani OS, and Zeman KL: Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv. 2012;25(Suppl 1):S10-S28.
15. Chrystyn H: Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol. 2001;51: 289-299.
16. Weers J, and Tarara T: The PulmoSphere platform for pulmonary drug delivery. Ther Deliv. 2014;5:277-295.
17. Sommerer K, Zanker D, and Ehlich H: Process Validation Report L-AC V01 (internal report). Inamed GmbH, Gauting, Germany; 2011.
18. Stass H, Nagelschmitz J, Kappeler D, Weimann B: Lung deposition of ciprofloxacin dry powder for inhalation in healthy subjects and patients suffering from COPD or non-CF bronchiectasis. Am J Resp Crit Care Med. 2013;187: Meeting Abstract A1507.
19. Devadason SG, Chan HK, Häussermann S, Kietzig C, Kuehl PJ, Newman S, Sommerer K, and Taylor G: Validation of radiolabeling of drug formulations for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv. 2012;25(suppl 1):S6-S9.
20. ICRP Publication 66. Human Respiratory Tract Model for Radiological Protection. Elsevier Science, New York; 1994.
21. Scheuch G: Expert report: Labeling of Ciprofloxacin dry powder with 99mTechnetium and possible implications on an in vivo deposition study. Inamed GmbH, Gauting, Germany; 2011.
22. Stass H, Kubitza D, Möller JG, and Delesen H: Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Br J Clin Pharmacol. 2005;59: 536-541.
23. Sörgel F, Naber KG, Jaehde U, Reiter A, Seelmann R, and Sigl G: Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am J Med. 1989;87(Suppl 5A):5A-62S.
24. Sörgel F, Naber KG, Jaehde U, Mahr G, Muth P, and Reiter A: Die gastrointestinale Sektretion von Antibiotika am Beispiel von Ciprofloxacin (Gastrointestinal secretion of antibiotics using the example of ciprofloxacin). Fortschritte Antimikrob Antineoplast Chemother. 1991;10:319-326.
25. Pitcairn GR, and Newman SP: Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med. 1997;10:187-198.
26. Häussermann S, Winnips C, Edelman J, Kappeler D, Herpich C, Ehlich H, Zanker D, Kietzig C, and Sommerer K: Lung deposition of alpha1-proteinase inhibitor (human) (A1-PI[H]) inhalation solution using two inhalation modes of the I-neb Adaptive Aerosol Delivery (AAD) system in healthy subjects and subjects with cystic fibrosis. J Aerosol Med Pulm Drug Deliv. 2016;29:242-250.
27. Shah A, Lettieri J, Blum R, Millikin S, Sica D, and Heller AH: Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. J Antimicrob Chemother. 1996;38:103-116.
28. Newman SP, Hirst PH, Pitcairn GR, and Clark AR: Understanding regional lung deposition data in gamma scintigraphy. In: RN Dalby, PR Byron, and SJ Farr (eds). Respiratory Drug Delivery VI. Interpharm Press Inc, Buffalo Grove, IL; pp. 9-15, 2006.
29. De Backer W, Devolder A, Poli G, Scerbi D, Monno R, Herpich C, Sommerer K, Meyer T, and Mariotti F: Lung deposition of BDP/Formeterol HFA mMDI in healthy volunteers, asthmatic and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23:137-148.
30. Tokimatsu I, Hiramatsu I, Morimoto T, Imai H, Suzaki Y, Stass H, Okumura K, and Kadota J: Safety, tolerability and pharmacokinetics of a single dose of ciprofloxacin dry powder for inhalation in Japanese patients with mild to moderate chronic obstructive pulmonary disease: A randomized controlled trial. Am J Respir Crit Care Med. 2013:183(Suppl):Abstract 20349.
31. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, and Weers JG: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003;124:360-366.
32. Wingender W, Graefe K-H, Gau W, Foster D, Beermann D, and Schacht P: Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol. 1984;3:355-359.
33. CoatesAL,DinhL,MacNeishCF,Rollin T,Gagnon S,HoSL, and Lands LC: Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med. 2000;13:169-178.
34. Lenney W, Edenborough F, Kho P, and Kovarik JM: Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros. 2011;10:9-14.
35. Haynes A, Geller D, Weers J, Ament B, Pavkov R, Malcolmson R, Debonnett L, Mastoridis P, Yadao T, and Heuerding S: Inhalation of tobramycin using simulated cystic fibrosis patient profiles. Pediatr Pulmonol. 2016 [Epub ahead of print]; DOI: 10.1002/ppul.23451
36. Stass H, Nagelschmitz J, Watz H, and Kirsten AM: Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD. Eur Resp J. 2012;40(Suppl 56): Abstract 2817.